News 
Market Data 
Discover
Replies to post #32696 on Cerebain Biotech Corp (fka CBBT) (CBBT)
-----Original Message-----
From: CEREBAIN BIOTECH INVESTOR RELATIONS DEPT
Sent: Thursday, September 29, 2022 9:38 AM
To: info@cerebain.com
Cc: ir@cerebain.com
Subject: [URL Verdict: Unknown][Source] Cerebain Biotech Has Made a
Capital Investment in Diabetes Reversal Group, LLC
Cerebain Biotech Has Made a Capital Investment in Diabetes Reversal Group,
LLC
September 29, 2022 08:30 AM Eastern Daylight Time
COSTA MESA, Calif.--(BUSINESS WIRE <https://www.businesswire.com/>
)--Cerebain Biotech Corp. (OTC: CBBT), (the "Company" or "Cerebain") today
announced that it has made a capital investment in Diabetes Reversal Group,
LLC.
"Cerebain is happy to announce it has made a capital investment in Diabetes
Reversal Group, LLC (DRG). We are confident in the growth potential of DRG
due to the size of the diabetes market and the demand for ways to reverse
this epidemic disease"
"Cerebain is happy to announce it has made a capital investment in Diabetes
Reversal Group, LLC (DRG). We are confident in the growth potential of DRG
due to the size of the diabetes market and the demand for ways to reverse
this epidemic disease," says Eric Clemons, CEO of Cerebain.
DRG has the only patented system in the world that reverses Type 2 Diabetes,
and they guarantee results. They have a 13-year track record and have helped
thousands of diabetics reverse their disease once and for all and get off
their medications.
"We are excited to expand nationally and internationally with our incredible
program, so we can help diabetics reverse this disease that causes so many
devastating complications," says Kristine Burke, MD, who is triple board
certified and the Chief Medical Officer of DRG.
About Cerebain Biotech Corp.
Cerebain Biotech Corp. is a development-stage medical device company focused
on the creation and clinical development of a minimally invasive implantable
device and a synthetic drug solution. The device leverages the clinically
observable, positive impact that Omentum stimulation has on cognitive
function as related to dementias, and in particular, Alzheimer's disease.
The corporate vision is based on these positive clinical observations. Visit
us at www.cerebain.com
<https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.cereba
in.com&esheet=52929737&newsitemid=20220929005273&lan=en-US&anchor=www.cereba
in.com&index=1&md5=b154a07d33fe397318003dd487ab07eb> or connect with us on
Twitter
<https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.twitte
r.com%2Fcerebainbiotech&esheet=52929737&newsitemid=20220929005273&lan=en-US&
anchor=Twitter&index=2&md5=63e8a6fdb41fa49bdd1dd4c1d0dba7b8> and Facebook
<https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.facebo
ok.com%2Fcerebainbiotech&esheet=52929737&newsitemid=20220929005273&lan=en-US
&anchor=Facebook&index=3&md5=be812231e4a6503fb83b43e19cfa2b16> to learn
more.
About Diabetes Reversal Group, LLC
Diabetes Reversal Group, LLC was founded to provide a natural diabetes
treatment, non-drug approach to helping people with metabolic and
nutritional imbalances. These imbalances can lead to many health problems
traditionally treated with invasive prescription drug therapy, such as Type
2 Diabetes, Neuropathy and Heart Disease. The Patented program developed by
DRG helps Type 2 Diabetes, Neuropathy and Heart Disease by restoring proper
metabolic function and nutritional balance. We have seen remarkable results
with the improvement or elimination of these conditions, working in
conjunction with your primary physician. Visit us at
https://diabetesreversalgroup.com
<https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fdiabetesr
eversalgroup.com&esheet=52929737&newsitemid=20220929005273&lan=en-US&anchor=
https%3A%2F%2Fdiabetesreversalgroup.com&index=4&md5=8cf8c3d9c86b037e67c1936a
a29f73f2> .
Forward Looking Statements
This news release contains certain "forward- looking statements."
Forward-looking statements are based on current expectations and assumptions
and are inherently subject to risks and uncertainties, some of which cannot
be predicted or quantified, and many of which are beyond the Company's
control. The forward-looking statements are also identified through the use
of words "believe," enable," "may," "will," "could," "intends," "estimate,"
"anticipate," "plan," "predict" "probable," "potential," "possible,"
"should," "continue," and other words of similar meaning. Actual results
could differ materially from these forward-looking statements as a result of
a number of risk factors detailed in the Company's reports filed with OTC
Markets. Given these risks and uncertainties, investors are cautioned not to
place undue reliance on such forward-looking statements and no assurances
can be given that such statements will be achieved.
Contacts
Investors:
Mr. Alan Klitenic
Cerebain Biotech Corp.
888.430.2221
info@cerebain.com
-----Original Message-----
From: ***************************************
Sent: Thursday, September 29, 2022 9:28 AM
To: ir@cerebain.com
Subject: RE: [URL Verdict: Unknown][Source] Cerebain Biotech Has
Made a Capital Investment in Diabetes Reversal Group, LLC
When is Cerebain going to do right by investors and clean up its ticker with
the SEC and make the stock tradeable once again.
Cerebain ignore the SEC and has blemished its name badly by doing so
Its time to acknowledge that and correct the matter
-----Original Message-----
From: CEREBAIN BIOTECH INVESTOR RELATIONS DEPT
Sent: Thursday, September 29, 2022 11:06 AM
To: ******************************
Subject: RE: [URL Verdict: Neutral][Source] Cerebain Biotech Has
Made a Capital Investment in Diabetes Reversal Group, LLC
Good Day Sir,
The IR Dept does not have any more information beyond what is here publicly.
This PR was released to shareholders and appears to show the company intent
to clean up the ticker for this all to make sense. There is absolutely no
guarantee that will happen of course. Everything is currently a work in
progress.
Regards,
Cerebain Biotech IR Dept
